Navigation Links
HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral
Date:12/17/2008

SAN JOSE, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") announced that it has filed a Comprehensive Patent Application with the U.S. Patent and Trademark Office for the use of an innovative and previously undeveloped compound with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well-being and social attraction.

"We are very excited about the potential of this naturally-occurring compound that we have labeled ER 303. Just inhaling very small quantities resulted in enhanced feelings of confidence, relaxation, affection, warmth, satisfaction and sensuality, in both men and women," a spokesperson indicated. Before the Company perfected the reproduction of this compound, it could only be found in coral reefs off the coasts of Newfoundland and in the waters off Brazil's Guiabinha Island.

"The Patent Application covers use in a wide range of products that may be enhanced and differentiated by the addition of ER 303, including those in the cosmetics and fragrance, personal care, environmental and household fields. Before filing for patent protection, the Company and its scientists have worked for more than eight years from the initial identification, reproducing the compound in the laboratory, conducting psychological and physiological scientific studies with men and women volunteers, and developing a manufacturing process for broad-scale production," the spokesperson also noted. The Company indicated that it is in the process of establishing http://www.ER303.com as its website which will contain additional information about the ER 303 technology and its potential applications for consumer product companies.

The Company has previously been granted broad-based worldwide patents for its initial compound, Androstadienone, which has been licensed to leading marketers, including Johnson & Johnson, Avon and Schwarkopf and Henkel and its affiliates. An HPS spokesperson indicated that the Company believes that this new compound should be of interest to the major consumer products companies around the world.

This news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2007, and Form 10-Q for the nine months ended September 30, 2008 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AMERIGROUP Files Shelf Registration Statement
2. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
3. Bally Total Fitness Files for Chapter 11 Bankruptcy Protection
4. Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution
5. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
6. Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign
7. VisiVite.com Files for Patent on Unique Macular Degeneration Supplement
8. State Fund Files an 8.9 Percent Premium Increase for 2009
9. KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q
10. Genesis Pharmaceuticals Files Counter Claims
11. Mary Hall, CEO of iHealthSpot, Inc., is Awarded Membership Into Fort Lauderdale City Limits "Profiles of Excellence"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... The California State ... convening academic faculty engaged in or interested in palliative care education and research. The ... be held in North County San Diego on Sept. 28 and 29, 2017, on ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Indiana Fiber Network ... the company later this year. Dyer started as the Chairman of the Management ... the establishment of the corporation including the recruitment of investor/owners and development of the ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February ... a letter to withdraw previous guidance issued by the Obama Administration ... guidance issued in May 2016 by the Obama Administration came in response to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Australien, 24. Februar 2017 ITL Limited, ... des Gesundheitsbereiches, ist erfreut, für das zum 31. ... entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine ... zum Wachstum" finden Sie hier . ... nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... USD 330.6 million by 2021 from USD 275.9 ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... industries, increasing spending on pharmaceutical R&D, and growth ... factors driving the market growth for particle counters. ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Disorder Drugs Price Analysis and Strategies - 2016" report to ... ... - 2016, provides drug pricing data and benchmarks in the global ... What are the key drugs marketed ...
Breaking Medicine Technology: